Quickstart Highlights
Selank is a synthetic heptapeptide analog of tuftsin with demonstrated anxiolytic and anti-asthenic (energy-boosting) properties in human clinical trials[1][2]. In Russian studies, intranasal Selank produced anxiolytic effects comparable to benzodiazepines without sedation or dependence potential[1].
Storage Instructions
Proper storage preserves peptide quality.
-
Lyophilized: Store at −20 °C (−4 °F) for long-term stability (several months); refrigeration at 2–8 °C (35.6–46.4 °F) acceptable for shorter periods[10].
-
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for approximately 1 month with minimal potency loss[10]. Prepare aliquots if needed and avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation and moisture uptake.
How It Works
Selank is a synthetic analog of the immunomodulatory peptide tuftsin, consisting of the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. In Russian clinical trials for anxiety disorders and neurasthenia, intranasal Selank produced anxiolytic effects comparable to benzodiazepines while also providing anti-asthenic (energy-boosting) benefits without sedative side effects or dependence potential[1][2]. Preclinical studies in primates demonstrated that intranasal Selank eliminated fear and anxiety behaviors with long-term stabilizing effects on neurobehavior[4]. Rodent studies confirmed robust anxiolytic efficacy comparable to classical tranquilizers[5]. While most published human data utilized intranasal dosing (the original formulation), subcutaneous administration has shown effectiveness in research settings with consistent absorption and ease of dose measurement[3]. A 14-day continuous course was well-tolerated and effective in human trials[2], and even high-dose applications have been explored for conditions such as attenuating opioid withdrawal symptoms in animal models[5].
Potential Benefits & Side Effects
Observations from clinical and preclinical literature.
- Produces anxiolytic effects comparable to benzodiazepines in human clinical trials without sedation or dependence risk[1].
- Provides anti-asthenic (energy-boosting) benefits alongside anxiety reduction[2].
- Induces lasting neurobehavioral changes; primate studies showed elimination of fear/anxiety behaviors with long-term stabilizing effects[4].
- Generally well tolerated in clinical studies; a 14-day continuous course was well-tolerated and effective in human trials[2].
- Occasional mild injection-site reactions (redness, minor irritation) may occur with subcutaneous administration; proper site rotation minimizes this risk.
- Lacks sedative side effects typical of classical anxiolytics, allowing for daytime use without impairment[1].
- Has been explored at higher doses for experimental applications such as attenuating opioid withdrawal symptoms, indicating a wide therapeutic range[5].
References
For laboratory and research use only. Minimum 98% purity. Not intended for human or animal consumption, medical,
diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. This protocol is
provided for educational and research purposes only and is not medical advice. The purchaser accepts full responsibility
for safe handling, storage and lawful use.